Delving into the Latest Updates on Guangdong Yinzhu Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	15
Immune System Diseases	8
Endocrinology and Metabolic Disease	4
Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Small molecule drug	21

Top 5 Target	Count

NF-κB(Nuclear factor NF-kappa-B complex)	1

[Translation] A clinical study evaluating the tolerability, safety, and preliminary efficacy of carboxytriazole soft capsules combined with osimertinib mesylate tablets as first-line treatment for patients with EGFR-sensitive mutation-positive, advanced non-small cell lung cancer with bone metastases.

评价羧胺三唑软胶囊联合甲磺酸奥希替尼片一线治疗EGFR敏感突变阳性、合并骨转移的晚期非小细胞肺癌受试者的耐受性、安全性以及初步疗效。

[Translation]

To evaluate the tolerability, safety, and preliminary efficacy of carboxytriazole soft capsules combined with osimertinib mesylate tablets as first-line treatment for patients with EGFR-sensitive mutation-positive advanced non-small cell lung cancer and bone metastases.

Start Date-

Sponsor / Collaborator

Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangdong Yinzhu Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

9

Preclinical

Phase 1

5

2

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YZ-0273	Hepatocellular Carcinoma More	Phase 2
YZ-0202	Lymphoma More	Phase 1
YZ-0213	Pancreatic Cancer More	Phase 1
YZ-0110	Rheumatoid Arthritis More	Phase 1
YZ-0217	Multiple Myeloma More	Phase 1